Now-04/30/13 Dendreon Provenge Prostate Cancer EMA CHMP Panel Result
Sentiment: Strong Buy
CAT monthly Meeting report April-2013 yet to be released but shall be before Wednesday on Provenge use and clinical concern for the Prostate Cancer and related documents on advanced therapies
FDA Calendar 2013
For biotech and drug companies, years of clinical trials and tens, if not hundreds, of millions of dollars in research and development culminate in a singular, all-important event: The decision by the U.S. Food and Drug Administration or its European counterparts to approve or reject a new medicine.
Investors certainly know all too well the importance of drug approval decisions on drug and biotech stocks. Next to clinical trial results, nothing drives a biotech stock higher or lower more than a U.S. or European drug approval decision.
The following calendar lists the dates of relevant FDA and European drug approval decisions, as well as FDA advisory committee meetings. The calendar will be updated regularly.